Novo Nordisk voluntarily withdraws EU authorisation of Velosulin
This article was originally published in Scrip
Executive Summary
Novo Nordisk has voluntarily withdrawn its EU marketing authorisation for human insulin product Velosulin because of commercial reasons. The company discontinued manufacturing Velosulin and another insulin product, Mixtard in 2007 – reasoning that this was to reflect the current trends in insulin usage.